All In Biotech

Drug Trial Radar · NCT00269880

A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Clinical Outcomes Following Percutaneous Coronary Intervention in Patients Treated With an Abciximab Bolus Plus 12-Hour Infusion Given With Either Standard-Dose Weight-Adjusted Heparin or Low-Dose Weight-Adjusted Heparin

Last checked: Nov 20, 2026Latest source record: May 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,792 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,792

Actual

Start

Feb 1995

Primary completion

Dec 1995

Study completion Dec 1995

Sponsor

Lead sponsor
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and effectiveness of abciximab, an anti-platelet therapy, versus placebo in patients undergoing percutaneous coronary intervention when administered in combination with two different heparin regimens. Please see attached results.

Conditions

  • Angioplasty, Transluminal, Percutaneous Coronary

Interventions

  • PlaceboDrug

    Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.

  • HeparinDrug

    Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.

  • AbciximabDrug

    Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death, myocardial infarction, or repeat revascularization within 6 monthsTime frame: up to 6 months
  2. Death, myocardial infarction, or severe myocardial ischemia leading to urgent repeat percutaneous coronary intervention or urgent coronary artery bypass surgery within 30 daysTime frame: Up to 30 Days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.